ERBB2 and breast carcinoma: Younger patients with aggressive forms of breast cancer, such as large tumors, lymph node involvement, negative steroid hormone status, low tumor differentiation, and high expression of HER-2/neu, are at a higher risk of relapse and distant metastases [16].